EP0721350A4 - Intrazelluläre immunisierung - Google Patents

Intrazelluläre immunisierung

Info

Publication number
EP0721350A4
EP0721350A4 EP94925693A EP94925693A EP0721350A4 EP 0721350 A4 EP0721350 A4 EP 0721350A4 EP 94925693 A EP94925693 A EP 94925693A EP 94925693 A EP94925693 A EP 94925693A EP 0721350 A4 EP0721350 A4 EP 0721350A4
Authority
EP
European Patent Office
Prior art keywords
intracellular immunization
immunization
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94925693A
Other languages
English (en)
French (fr)
Other versions
EP0721350A1 (de
Inventor
Lingxun Duan
Roger Pomerantz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP0721350A1 publication Critical patent/EP0721350A1/de
Publication of EP0721350A4 publication Critical patent/EP0721350A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Luminescent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP94925693A 1993-07-30 1994-07-28 Intrazelluläre immunisierung Withdrawn EP0721350A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99870 1987-09-22
US9987093A 1993-07-30 1993-07-30
PCT/US1994/008448 WO1995003832A1 (en) 1993-07-30 1994-07-28 Intracellular immunization

Publications (2)

Publication Number Publication Date
EP0721350A1 EP0721350A1 (de) 1996-07-17
EP0721350A4 true EP0721350A4 (de) 1999-08-11

Family

ID=22277017

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94925693A Withdrawn EP0721350A4 (de) 1993-07-30 1994-07-28 Intrazelluläre immunisierung

Country Status (5)

Country Link
EP (1) EP0721350A4 (de)
JP (1) JPH09500902A (de)
AU (1) AU682206B2 (de)
CA (1) CA2168349A1 (de)
WO (1) WO1995003832A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194291T1 (de) * 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
MXPA02001877A (es) 1999-08-23 2002-08-20 Dana Farber Cancer Inst Inc Pd-1, un receptor para b7-4, y usos del mismo.
DE60034817T2 (de) 1999-12-30 2008-01-31 President And Fellows Of Harvard College, Cambridge Verfahren zur modulierung der aktivität von th2-zellen durch modulierung der aktivität von xbp-1
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
AU2009298879A1 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College SIRT4 and uses thereof
DK2342226T3 (en) 2008-09-26 2016-09-26 Dana Farber Cancer Inst Inc HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
BR112012007137A2 (pt) 2009-09-30 2015-09-15 Harvard College metodos para modulacao da autofagia por meio da modulacao de produtos genicos inibidores da autofagia
CA2778953C (en) 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
EP2561356B1 (de) 2010-04-18 2016-08-03 Yeda Research and Development Co. Ltd. Moleküle und deren verwendung zur behandlung von erbb/erbb liganden - assozierten krankheiten
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
WO2013063613A2 (en) * 2011-10-28 2013-05-02 University Of Maryland Methods and compositions related to intracellular neutralization by igg
US20150018406A1 (en) 2012-03-09 2015-01-15 Cornell University Modulation of breast cancer growth by modulation of xbp1 activity
WO2014022759A1 (en) 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP3293275B1 (de) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Zusammensetzung und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
EP3027225B1 (de) 2013-07-31 2021-03-24 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur modulierung der thermogenese mit transformierender wachstumsfaktor alpha
US9957506B2 (en) 2013-09-25 2018-05-01 Cornell University Compounds for inducing anti-tumor immunity and methods thereof
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP3094736A4 (de) 2014-01-14 2017-10-25 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von melanom mit pd-l1-isoformen
ES2799404T3 (es) 2014-07-15 2020-12-17 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Polipéptidos de CD44 aislados y usos de los mismos
BR112017009297B1 (pt) 2014-11-05 2024-02-15 Annexon, Inc Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
WO2016079736A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
EP3229837A4 (de) 2014-12-08 2018-05-30 Dana-Farber Cancer Institute, Inc. Verfahren zur hochregulierung von immunantworten unter verwendung von kombinationen aus anti-rgmb- und anti-pd1-wirkstoffen
EP3268025B1 (de) 2015-03-10 2020-05-06 University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
WO2016181393A1 (en) 2015-05-11 2016-11-17 Yeda Research And Development Co. Ltd. Citrin inhibitors for the treatment of cancer
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
US20190178888A1 (en) 2016-01-11 2019-06-13 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
US20200172604A1 (en) 2017-05-23 2020-06-04 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
EP4096647A1 (de) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Behandlung einer akuten lebererkrankung mit tlr-mik-inhibitoren
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling the ubiquitination process of mlkl for disease treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002610A1 (en) * 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002610A1 (en) * 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FEINBERG M B ET AL: "INTRACELLULAR IMMUNIZATION: TRANS-DOMINANT MUTANTS OF HIV GENE PRODUCTS AS TOOLS FOR THE STUDY AND INTERRUPTION OF VIRAL REPLICATION", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 8, no. 6, 1 June 1992 (1992-06-01), pages 1013 - 1022, XP000199752 *
MARASCO WA ET AL.: "Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody", PNAS, vol. 90, no. 16, 15 August 1993 (1993-08-15), pages 7889 - 93, XP000389696 *
See also references of WO9503832A1 *

Also Published As

Publication number Publication date
AU7551394A (en) 1995-02-28
EP0721350A1 (de) 1996-07-17
WO1995003832A1 (en) 1995-02-09
JPH09500902A (ja) 1997-01-28
CA2168349A1 (en) 1995-02-09
AU682206B2 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
EP0721350A4 (de) Intrazelluläre immunisierung
GB9419218D0 (en) Methods
HU9601504D0 (en) Infuser
ZA947828B (en) Vaccines
DE59407177D1 (en) 2-fluorcycloyhexen-derivate
GB9325496D0 (en) Vaccines
GB2284506B (en) Thermostat
DE59408644D1 (en) Jacquardmaschine
DE59408733D1 (en) Metallhalogenidentladungslampe
GB9315306D0 (en) Methods
GB9322702D0 (en) Vaccines
GB9315351D0 (en) Methods
GB9315340D0 (en) Methods
DE59407310D1 (en) Phenylazotriazolopyridinfarbstoffe
GB9322808D0 (en) Vaccines
AU122479S (en) Label-printer
GB9308780D0 (en) Methods
GB9315298D0 (en) Methods
DE59403125D1 (en) Hohlleitermultiplexer/-demultiplexer
GB9315271D0 (en) Methods
GB9315341D0 (en) Methods
CA73639S (en) Handstamp
CA72257S (en) Floorstand
ZA949128B (en) Vaccine
GB9323754D0 (en) Vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990624

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000508

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 48/00 A, 7C 12N 5/10 B, 7C 12N 15/13 B, 7C 12N 15/85 B, 7C 12N 15/86 B, 7A 61P 31/00 B, 7A 61P 33/00 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020703